APP, amyloid beta precursor protein, 351

N. diseases: 485; N. variants: 114
Disease: Memory impairment ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE MCH improved memory impairment in both models and reduced soluble amyloid beta in the cerebral cortex of APP/PS1 transgenic mice. 31183806 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE SEN1500, an orally bioavailable and CNS-penetrant Aβ aggregation inhibitor, has previously been shown to reduce spatial learning and memory deficits in an APP transgenic mouse model. 28917978 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here, we tested whether dietary choline supplementation throughout life reduces AD-like pathology and rescues memory deficits in the APP/PS1 mouse model of AD. 31560162 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 AlteredExpression phenotype BEFREE Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. 11950278 2002
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE To investigate if increasing plasma apoA-I/HDL levels ameliorates AD-like memory deficits and amyloid-β (Aβ) deposition, we generated a line of triple transgenic (Tg) mice overexpressing mutant forms of amyloid-β precursor protein (APP) and presenilin 1 (PS1) as well as human apoA-I (AI). 20847045 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE FGF2 treatment attenuated spatial memory deficits, reduced amyloid-β (Aβ) and tau pathologies, decreased inducible nitric oxide synthase expression, and increased the number of astrocytes in the dentate gyrus in APP 23 mice compared with the vehicle-treated controls. 25457554 2015
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF-β/Smad2/STAT3 signaling. 28366226 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Amyloid-β peptide 42 (Aβ42) is produced through the sequential proteolytic cleavage of APP by β- and γ-secretase and causes the synaptic dysfunction associated with memory impairment in Alzheimer's disease. 24373902 2014
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Geniposide attenuates mitochondrial dysfunction and memory deficits in APP/PS1 transgenic mice. 25034042 2014
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE The spatial learning and memory deficit from the 8-month-old APP/PS1 mice was observed in the Y-maze test and fear conditioning task. 31286344 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE We show that treatment aimed at preventing PV interneurons from becoming hyperexcitable is sufficient to restore PV interneuron properties to wild-type levels, reduce inhibitory input onto pyramidal cells, and rescue memory deficits in APP/PS1 mice. 31431685 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here, we demonstrated that HFD markedly deteriorated memory impairment and increased β-amyloid (Aβ) oligomers as well as Aβ deposition in amyloid precursor protein (APP) transgenic mice, which was reversed by exposure to an enriched environment for 10 weeks, despite the continuation of HFD. 22197104 2012
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE These findings show a selective upregulation of astroglial B1R in the APP mouse brain, and the capacity of the B1R antagonist to abrogate amyloidosis, cerebrovascular and memory deficits. 23642031 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE TEN has potential benefit in treating learning and memory deficits in APP/PS1 transgenic AD mice, and its effects may be associated with reversing AD pathology-induced neuronal apoptosis. 31664284 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE Transgenic mice carrying AD-causing mutations in APP develop spontaneous age-related beta-amyloid (A beta) deposition and memory impairment. 9052714 1997
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype CTD_human Virgin coconut oil (VCO) by normalizing NLRP3 inflammasome showed potential neuroprotective effects in Amyloid-β induced toxicity and high-fat diet fed rat. 29729307 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Behavioral assessment using Barnes maze showed that APP + PS1 rats exhibited a larger learning and memory deficit than APP21 rats. 27388605 2016
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE APP/PS1 mice and KCa3.1<sup>-/-</sup>/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits. 30442153 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype CTD_human Evaluation of the protective role of melatonin on the behavioral effects of aluminum in a mouse model of Alzheimer's disease. 19770021 2009
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Administration of PPARA agonists decreases amyloid pathology and reverses memory deficits and anxiety symptoms in APP-PSEN1ΔE9 mice. 30898012 2020
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Exposure of isoflurane exhibited significant neuroapoptosis, Aβ generation, tau phosphorylation, and learning and memory impairment in APP/PS1 mice in the presence of Zn deficiency. 27586008 2016
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE In vivo treatment of London APP mice, expressing the WT beta-secretase site, with these inhibitors resulted in substantial improvement in memory deficit assessed by the Morris water maze test. 18184658 2008
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here, we show that Sod1 deficiency in an amyloid precursor protein-overexpressing mouse model (AD mouse, Tg2576) accelerated Aβ oligomerization and memory impairment as compared with control AD mouse and that these phenomena were basically mediated by oxidative damage. 22072713 2011
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE The amyloid precursor protein + presenilin-1 (APP+PS1) transgenic mouse is a model for amyloid deposition, and like AD, the mice develop memory deficits as amyloid deposits accumulate. 12832546 2003
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Treatment with the active compounds reduced cognitive and memory deficits and damaged cell ultrastructure in APP/PS1 mice. 31816602 2019